Working… Menu

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01841463
Recruitment Status : Suspended (Sponsor decision not related to patient safety)
First Posted : April 26, 2013
Last Update Posted : September 4, 2014
Melanoma Research Foundation Breakthrough Consortium
Information provided by (Responsible Party):
Piramal Enterprises Limited

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : March 2015
Estimated Study Completion Date : March 2016